Randomized controlled trials in patients with COVID-19: a systematic review and critical appraisal.

ABSTRACT:

Objectives

This study aimed to describe the prevalence of risks of bias in randomized trials of therapeutic interventions for COVID-19.

Methods

Systematic review and risk of bias assessment performed by two independent reviewers of a random sample of 40 randomized trials of therapeutic interventions for moderate-severe COVID-19. We used the RoB 2.0 tool to assess the risk of bias, which evaluates bias under five domains as well as an overall assessment of each trial as high or low risk of bias.

Results

Of the 40 included trials, 19 (47%) were at high risk of bias, and this was particularly frequent in trials from low-middle income countries (11/14, 79%). Potential deviations to intended interventions (i.e., control participants accessing experimental treatments) were

SUBMITTER: Kudhail K 

PROVIDER: S-EPMC9113951 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature